M&A Acquirer Playbook

ABBOTT LABORATORIES acquisition history.

Every deal, price, and strategic rationale.

Company ABBOTT LABORATORIES

SEC CIK 0000001800

Tracked filings EDGAR · 8-K

Total deals tracked

Disclosed 8-K acquisitions, 2001 — present.

Aggregate disclosed value

$80B

More than $80 billion deployed across 16 disclosed acquisitions — spanning medical devices, diagnostics and pharmaceuticals.

Active acquisition years

2001 · 2004 · 2006 · 2009 · 2010 · 2014 · 2017 · 2021 · 2023 · 2026

steady, large-scale dealmaking across two decades.

Primary sectors

Medical devices , diagnostics (Alere, Exact Sciences, Vysis, i-STAT) and pharmaceuticals (Solvay, Piramal, CFR, Kos, BASF/Knoll)

St. Jude Medical, Guidant Vascular, Advanced Medical Optics, Cardiovascular Systems.

Verified 16 deals on this page · sourced from SEC filings

All cross-references covered.

Timeline

16 deals, $80B deployed.

Plotted by close date where disclosed, otherwise announcement. Click any marker to jump to the deal entry.

The playbook

The rationale that repeats.

Three patterns show up across ABBOTT LABORATORIES's deal book — what the team buys, how it pays, and how it integrates. The patterns are the throughline; the individual deals below are the evidence.

Acquisition criteria

Buy the category leader, then build the franchise.

Abbott's biggest deals each established or vaulted it to leadership in an entire category: St. Jude Medical in cardiovascular devices, Alere in point-of-care diagnostics, Advanced Medical Optics in eye care, and Exact Sciences in cancer screening. Abbott repeatedly described the goal as becoming "a premier" or "the leading" player in the target's market rather than acquiring a single product.

Exact Sciences CorporationSt. Jude MedicalAlere Inc.CFR Pharmaceuticals S.A.Solvay Pharmaceuticals

Capital deployment

Three engines: devices, diagnostics, and pharma.

Rather than concentrating in one area, Abbott has used M&A to feed all three of its growth platforms in parallel, vascular and structural-heart devices (Guidant Vascular, St. Jude, Cardiovascular Systems, Walk Vascular), diagnostics (Vysis, i-STAT, Alere, Exact Sciences), and pharmaceuticals (BASF/Knoll, Kos, Solvay, Piramal, CFR). The Knoll/BASF deal alone brought in the antibody Abbott later commercialized as HUMIRA.

Exact Sciences CorporationSt. Jude MedicalAlere Inc.CFR Pharmaceuticals S.A.Solvay Pharmaceuticals

Integration approach

Tender offers and emerging-markets reach.

Abbott favored all-cash tender-offer structures for many deals (Vysis, i-STAT, AMO, Kos, Facet Biotech, CFR), often locking in majority support before launch. It also used acquisitions to globalize, Solvay and Piramal expanded its emerging-markets pharmaceutical footprint, and Piramal and CFR made Abbott a branded-generics leader in India and Latin America respectively.

Exact Sciences CorporationSt. Jude MedicalAlere Inc.CFR Pharmaceuticals S.A.Solvay Pharmaceuticals

Deal book · 16 acquisitions

The full deal book.

16 acquisitions. Click any row to see the deal value, financing structure, target revenue, executive commentary, and the original SEC filing — the evidence behind the patterns above.

Exact Sciences is a leader in large and fast-growing cancer screening and precision oncology diagnostics, best known for the Cologuard colorectal cancer screening test and the Oncotype DX cancer recurrence assays.

Why it was attractive

01 Leadership position in cancer screening with the Cologuard franchise and a precision-oncology portfolio in a large
02 fast-growing diagnostics segment

Capabilities acquired

colorectal cancer screeningprecision oncology diagnosticsblood-based and molecular cancer testingmulti-cancer early detection pipeline

Abbott has repeatedly taken on the world's most challenging health issues and made a meaningful impact on the lives of people in areas such as diabetes, cardiovascular disease and infectious disease. With Exact Sciences, we will do the same in cancer.

Robert B. Ford Chairman and CEO, Abbott

With the legacy and deep expertise of the Exact Sciences team, we're ready to transform cancer care.

Abbott management Exact Sciences completion release

Deal value

$21B

approximately $21 billion equity value (about $23 billion including net debt)

Terms

AnnouncedNov 2025

ClosedMar 2026

StructureFull acquisition

Considerationall cash

Deal facts

GeographyMadison, Wisconsin, USA

SegmentDiagnostics — cancer screening & precision oncology

Integration unitIntegrated into Abbott's Diagnostics business

Integration timelineAnnounced November 20, 2025; completed March 23, 2026.

Not disclosed in filing Target revenue / EBITDA · Cash impact / synergies

Fundingall cash.

SEC 8-K · Exact Sciences Corporation

St. Jude Medical is a global medical device company with leading positions in cardiac rhythm management, atrial fibrillation, heart failure and neuromodulation.

Why it was attractive

01 Industry-leading cardiovascular and neuromodulation pipeline complementary to Abbott's existing vascular and diagnostics franchises

Capabilities acquired

cardiac rhythm managementheart failureatrial fibrillationstructural heartchronic pain and movement disorder neuromodulation

Bringing together these two great companies will create a premier medical device business and immediately advance Abbott's strategic and competitive position.

Miles D. White Chairman and CEO, Abbott

Deal value

$25B

approximately $25 billion equity value ($46.75 cash + 0.8708 Abbott shares per share, ~$85/share; ~$30 billion total value including debt)

Terms

AnnouncedApr 2016

ClosedJan 2017

StructureFull acquisition

Considerationcombination

Financials

Cash impact / synergiesAbbott projected approximately $500 million of annual pre-tax synergies by 2020.

Deal facts

GeographySt. Paul, Minnesota, USA

SegmentMedical devices — cardiovascular & neuromodulation

Integration unitIntegrated into Abbott's Medical Devices business

Integration timelineAnnounced April 28, 2016; completed January 4, 2017.

Not disclosed in filing Target revenue / EBITDA

Fundingcombination (cash and stock).

SEC 8-K · St. Jude Medical

Alere is a global leader in point-of-care diagnostics, providing rapid tests across infectious disease, cardiometabolic and toxicology testing close to the patient.

Why it was attractive

01 Leadership in the ~$5.5 billion point-of-care testing market
02 significantly expanding Abbott's global diagnostics presence

Capabilities acquired

point-of-care infectious disease testingcardiometabolic diagnosticstoxicologyrapid diagnostic platforms

We want to offer our customers the best and broadest diagnostics solutions. Alere helps us do that.

Miles D. White Chairman and CEO, Abbott

Our leading platforms and global presence in point-of-care diagnostics, combined with Abbott's broad portfolio of market-leading products, position the combined company for strong growth.

Namal Nawana President and CEO, Alere

Deal value

$5.3B

$51 per share, approximately $5.3 billion at close (originally announced at $56 per share / ~$5.8 billion equity value)

Terms

AnnouncedFeb 2016

ClosedOct 2017

StructureFull acquisition

Considerationall cash

Deal facts

GeographyWaltham, Massachusetts, USA

SegmentDiagnostics — point of care testing

Integration unitIntegrated into Abbott's Diagnostics business

Integration timelineAnnounced February 1, 2016; price renegotiated to $51/share in April 2017; completed October 3, 2017.

Not disclosed in filing Target revenue / EBITDA · Cash impact / synergies

Fundingall cash.

SEC 8-K · Alere Inc.

CFR Pharmaceuticals is a Latin America-based branded generics pharmaceutical company with a broad portfolio of well-known, trusted products and a strong presence across the fast-growing region.

Why it was attractive

01 More than doubled Abbott's branded generics sales and presence in the fast-growing Latin American market

Capabilities acquired

branded genericsLatin American distribution and manufacturingspecialty pharmaceuticals

By adding CFR's portfolio of well-known, trusted products, Abbott has taken another key step in actively shaping its portfolio to better meet the evolving needs of health care.

Abbott CFR completion news release

Deal value

$2.9B

approximately $2.9 billion

Terms

AnnouncedMay 2014

ClosedSep 2014

StructureFull acquisition

Considerationall cash

Deal facts

GeographySantiago, Chile (Latin America)

SegmentPharmaceuticals — branded generics

Integration unitIntegrated into Abbott's Established Pharmaceuticals business

Integration timelineAnnounced May 16, 2014; U.S. and Chilean tender offers expired September 23, 2014; acquisition of control announced September 26, 2014.

Not disclosed in filing Target revenue / EBITDA · Cash impact / synergies

Fundingall cash (tender offer).

SEC 8-K · CFR Pharmaceuticals S.A.

Solvay Pharmaceuticals is the pharmaceuticals business of the Solvay Group, with a diversified portfolio of branded specialty pharmaceutical products and a strong international, particularly emerging-markets, footprint.

Why it was attractive

01 Diversified pharmaceutical portfolio with a strong emerging-markets growth platform

Capabilities acquired

specialty pharmaceuticalsvaccinesemerging-markets commercial platformcardiometabolic and other therapeutic franchises

Deal value

$4.5B

EUR 4.5 billion (approximately $6.2 billion) in cash, plus potential additional payments

Terms

AnnouncedSep 2009

ClosedFeb 2010

StructureFull acquisition

Considerationall cash

Deal facts

GeographyBrussels, Belgium (global, emerging-markets weighted)

SegmentPharmaceuticals

Integration unitIntegrated into Abbott's pharmaceutical products business

Integration timelineAnnounced September 28, 2009; completed February 15, 2010 (announced February 16, 2010).

Not disclosed in filing Target revenue / EBITDA · Cash impact / synergies

Fundingall cash.

SEC 8-K · Solvay Pharmaceuticals

Piramal's Healthcare Solutions business is a leading branded generics pharmaceutical operation in India with a broad product portfolio and extensive local distribution.

Why it was attractive

01 Top market position in the fast-growing Indian pharmaceutical market

Capabilities acquired

branded genericsIndian pharmaceutical distribution and manufacturingemerging-markets commercial reach

Deal value

$2.2B

$2.2 billion up-front plus $400 million annually for four years beginning in 2011 (approximately $3.72 billion total)

Terms

AnnouncedMay 2010

ClosedSep 2010

StructureAsset purchase

Considerationall cash

Deal facts

GeographyMumbai, India

SegmentPharmaceuticals — branded generics (India)

Integration unitIntegrated into Abbott's Established Products / pharmaceutical business in India

Integration timelineAnnounced May 21, 2010; completed September 8, 2010.

Not disclosed in filing Target revenue / EBITDA · Cash impact / synergies

Fundingall cash (up-front plus deferred payments).

SEC 8-K · Piramal Healthcare Solutions (Piramal Healthcare's Healthcare Solutions business)

Advanced Medical Optics is a leader in eye care, holding the number one position in LASIK surgical devices, number two in the cataract surgical device market and number three in the contact lens care market.

Why it was attractive

01 Leadership positions across the large and growing eye care market

Capabilities acquired

LASIK surgical systemscataract surgical devicescontact lens care productsophthalmic surgical equipment

Deal value

$2.8B

$22.00 per share, approximately $2.8 billion including debt

Terms

AnnouncedJan 2009

ClosedFeb 2009

StructureFull acquisition

Considerationall cash

Deal facts

GeographySanta Ana, California, USA

SegmentMedical devices — vision care

Integration unitBecame Abbott Medical Optics (AMO)

Integration timelineAnnounced January 12, 2009; tender completed; acquisition completed February 25, 2009.

Not disclosed in filing Target revenue / EBITDA · Cash impact / synergies

Fundingall cash (tender offer).

SEC 8-K · Advanced Medical Optics

Guidant's vascular intervention and endovascular solutions businesses, including coronary and peripheral stent and angioplasty product lines, acquired from Boston Scientific as a condition of Boston Scientific's acquisition of Guidant.

Why it was attractive

01 Established Abbott as a major player in the global vascular intervention market with a drug-eluting stent pipeline

Capabilities acquired

coronary stentsangioplasty systemsendovascular and peripheral vascular devicesdrug-eluting stent pipeline

Deal value

$4.1B

approximately $4.1 billion (acquired from Boston Scientific in connection with its acquisition of Guidant)

Terms

AnnouncedJan 2006

ClosedApr 2006

StructureCarve-out

Considerationcombination

Deal facts

GeographySanta Clara, California, USA

SegmentMedical devices — vascular intervention

Integration unitBecame Abbott Vascular

Integration timelineAnnounced January 2006 (contingent on Boston Scientific's Guidant deal); completed April 21, 2006.

Not disclosed in filing Target revenue / EBITDA · Cash impact / synergies

Fundingcombination (cash plus a loan and milestone payments).

SEC 8-K · Guidant's vascular intervention and endovascular businesses

Kos Pharmaceuticals is a specialty pharmaceutical company focused on cardiometabolic and respiratory products, including the Niaspan and Advicor lipid-management franchises.

Why it was attractive

01 Complementary lipid-management and cardiometabolic franchise
02 shareholders owning ~53% of shares committed to tender
03 assuring closing

Capabilities acquired

lipid management (NiaspanAdvicor)cardiometabolic specialty pharmaceuticalsrespiratory products

Deal value

$3.7B

$78.00 per share in cash (approximately $3.7 billion)

Terms

AnnouncedNov 2006

ClosedDec 2006

StructureFull acquisition

Considerationall cash

Deal facts

GeographyCranbury, New Jersey, USA

SegmentPharmaceuticals — cardiometabolic / lipid management

Integration unitIntegrated into Abbott's pharmaceutical business

Integration timelineMerger agreement signed November 5, 2006; tender offer commenced November 2006; completed December 14, 2006.

Not disclosed in filing Target revenue / EBITDA · Cash impact / synergies

Fundingall cash (tender offer and merger).

SEC 8-K · Kos Pharmaceuticals

BASF's pharmaceutical business, operated as Knoll Pharmaceuticals, including the global operations and an early-stage anti-inflammatory antibody (later commercialized by Abbott as HUMIRA).

Why it was attractive

01 Global pharmaceutical scale plus a pipeline antibody that became one of the best-selling drugs in history

Capabilities acquired

branded pharmaceuticalsimmunology and anti-inflammatory pipelineglobal pharmaceutical operations

Deal value

$6.9B

approximately $6.9 billion in cash

Terms

AnnouncedDec 2000

ClosedMar 2001

StructureFull acquisition

Considerationall cash

Deal facts

GeographyLudwigshafen, Germany (global operations)

SegmentPharmaceuticals

Integration unitIntegrated into Abbott's pharmaceutical business

Integration timelineAnnounced December 2000; completed March 2, 2001.

Not disclosed in filing Target revenue / EBITDA · Cash impact / synergies

Fundingall cash.

SEC 8-K · BASF's pharmaceutical business (Knoll)

Vysis is a genomic disease management company specializing in molecular cytogenetic and FISH-based diagnostic products for cancer and genetic disease.

Why it was attractive

01 Pioneering molecular/FISH diagnostic technology that became the basis of Abbott Molecular

Capabilities acquired

FISH (fluorescence in situ hybridization) diagnosticsmolecular cytogeneticsgenomic disease management

Deal value

$355M

$30.50 per share in cash (approximately $355 million)

Terms

AnnouncedOct 2001

ClosedDec 2001

StructureFull acquisition

Considerationall cash

Deal facts

GeographyDowners Grove, Illinois, USA

SegmentDiagnostics — molecular / genomic diagnostics

Integration unitBecame part of Abbott Molecular / Abbott Diagnostics

Integration timelineTender offer commenced October 30, 2001 at $30.50/share; offer expired November 29, 2001; completed early December 2001.

Not disclosed in filing Target revenue / EBITDA · Cash impact / synergies

Fundingall cash (tender offer and merger).

SEC 8-K · Vysis

i-STAT Corporation is a maker of handheld point-of-care blood analysis systems used at the patient's bedside.

Why it was attractive

01 Established Abbott in handheld point-of-care testing
02 a long-running growth platform (Abbott i-STAT)

Capabilities acquired

handheld point-of-care blood analyzersblood gas and chemistry cartridgesnear-patient diagnostic testing

Deal value

$392M

$15.35 per share in cash (approximately $392 million)

Terms

AnnouncedDec 2003

ClosedJan 2004

StructureFull acquisition

Considerationall cash

Deal facts

GeographyEast Windsor, New Jersey, USA

SegmentDiagnostics — point of care testing

Integration unitBecame Abbott Point of Care (i-STAT)

Integration timelineMerger agreement dated December 12, 2003; tender offer at $15.35/share; completed January 2004.

Not disclosed in filing Target revenue / EBITDA · Cash impact / synergies

Fundingall cash (tender offer and merger).

SEC 8-K · i-STAT Corporation

Facet Biotech is a biotechnology company with a portfolio of biologic drug candidates, including programs in multiple sclerosis and oncology and an antibody-engineering platform.

Why it was attractive

01 Added a biologics pipeline and antibody-engineering technology to Abbott's pharmaceutical research

Capabilities acquired

biologics R&Dantibody engineering platformmultiple sclerosis and oncology drug candidates

Deal value

$450M

$27.00 per share in cash (approximately $450 million; net of cash ~$722 million enterprise / ~$450M net)

Terms

AnnouncedMar 2010

ClosedApr 2010

StructureFull acquisition

Considerationall cash

Deal facts

GeographyRedwood City, California, USA

SegmentBiopharmaceuticals — early-stage R&D

Integration unitIntegrated into Abbott's pharmaceutical R&D

Integration timelineTender offer at $27.00/share commenced March 2010; completed April 20, 2010.

Not disclosed in filing Target revenue / EBITDA · Cash impact / synergies

Fundingall cash (tender offer and merger).

SEC 8-K · Facet Biotech Corporation

Cardiovascular Systems, Inc. (CSI) makes an atherectomy system used in treating peripheral and coronary artery disease, adding complementary technologies to Abbott's portfolio of vascular device offerings.

Why it was attractive

01 Complementary atherectomy technology for Abbott Vascular

Capabilities acquired

atherectomy systemsperipheral artery disease treatmentcoronary artery disease treatmentvascular devices

On April 27, 2023, Abbott completed the acquisition of Cardiovascular Systems, Inc. (CSI). CSI's atherectomy system, which is used in treating peripheral and coronary artery disease, adds complementary technologies to Abbott's portfolio of vascular device offerings.

Abbott FY2023 10-K Item 1 Business

Deal value

Not disclosed

Terms

Disclosed in 8-KApr 2023

StructureFull acquisition

ConsiderationNot disclosed

Deal facts

GeographySt. Paul, Minnesota, USA

SegmentMedical devices — vascular

Integration unitIntegrated into Abbott's Medical Devices (Vascular) business

Integration timelineCompleted April 27, 2023.

Not disclosed in filing Target revenue / EBITDA · Cash impact / synergies

Funding(not disclosed).

SEC 8-K · Cardiovascular Systems

Bigfoot Biomedical develops connected insulin-management solutions, furthering Abbott's efforts to develop connected solutions for making diabetes management more personal and precise.

Why it was attractive

01 Connected insulin-management technology that complements Abbott's FreeStyle Libre diabetes franchise

Capabilities acquired

connected insulin dosing systemsdiabetes management softwareintegration with continuous glucose monitoring

On September 22, 2023, Abbott completed the acquisition of Bigfoot Biomedical, Inc. (Bigfoot), which will further Abbott's efforts to develop connected solutions for making diabetes management more personal and precise.

Abbott FY2023 10-K Item 1 Business

Deal value

Not disclosed

Terms

Disclosed in 8-KSep 2023

StructureFull acquisition

ConsiderationNot disclosed

Deal facts

GeographyMilpitas, California, USA

SegmentMedical devices — diabetes care

Integration unitIntegrated into Abbott's Diabetes Care business

Integration timelineCompleted September 22, 2023.

Not disclosed in filing Target revenue / EBITDA · Cash impact / synergies

Funding(not disclosed).

SEC 8-K · Bigfoot Biomedical

Walk Vascular is a commercial-stage medical device company with a minimally invasive thrombectomy system designed to remove peripheral blood clots; its peripheral thrombectomy system has been incorporated into Abbott's existing endovascular portfolio.

Why it was attractive

01 Commercial-stage peripheral thrombectomy system complementary to Abbott's endovascular portfolio

Capabilities acquired

peripheral thrombectomy systemsminimally invasive blood-clot removalendovascular devices

In September 2021, Abbott acquired Walk Vascular, LLC (Walk Vascular), a commercial-stage medical device company with a minimally invasive thrombectomy system designed to remove peripheral blood clots. Walk Vascular's peripheral thrombectomy system has been incorporated into Abbott's existing endovascular portfolio.

Abbott FY2023 10-K financial statements note

Deal value

Not disclosed

Terms

Disclosed in 8-KSep 2021

StructureFull acquisition

ConsiderationNot disclosed

Deal facts

GeographyIrvine, California, USA

SegmentMedical devices — vascular

Integration unitIntegrated into Abbott's endovascular portfolio

Integration timelineCompleted September 2021.

Not disclosed in filing Target revenue / EBITDA · Cash impact / synergies

Funding(not disclosed).

SEC 8-K · Walk Vascular

End of deal book

16 acquisitions · $80B deployed ·2001 — present

VectorShift for deal teams

Bring this depth
to every deal.

Every figure on this page came from public filings. Point the same pipeline at the documents your team actually works on — CIMs, management decks, expert calls, portfolio reports — and get research like this in minutes, not weeks.

Contact sales See platform

16 deals, $80B deployed.

The rationale that repeats.

Buy the category leader, then build the franchise.

Three engines: devices, diagnostics, and pharma.

Tender offers and emerging-markets reach.

The full deal book.

Bring this depthto every deal.

Bring this depth
to every deal.